Comparing SG&A Expenses: Ligand Pharmaceuticals Incorporated vs Iovance Biotherapeutics, Inc. Trends and Insights

Biotech SG&A Expenses: Iovance vs. Ligand, 2014-2023

__timestampIovance Biotherapeutics, Inc.Ligand Pharmaceuticals Incorporated
Wednesday, January 1, 2014933577222570000
Thursday, January 1, 20151239000024378000
Friday, January 1, 20162560200026621000
Sunday, January 1, 20172126200028653000
Monday, January 1, 20182843000037734000
Tuesday, January 1, 20194084900041884000
Wednesday, January 1, 20206021000064435000
Friday, January 1, 20218366400057483000
Saturday, January 1, 202210409700070062000
Sunday, January 1, 202310691600052790000
Loading chart...

Data in motion

SG&A Expenses: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing expenses is crucial for sustaining growth and innovation. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Ligand Pharmaceuticals Incorporated and Iovance Biotherapeutics, Inc. over the past decade. From 2014 to 2023, Iovance Biotherapeutics saw a staggering increase of over 1,000% in SG&A expenses, peaking at approximately $107 million in 2023. In contrast, Ligand Pharmaceuticals experienced a more modest growth of around 134%, reaching about $53 million in the same year. This divergence highlights Iovance's aggressive expansion strategy, while Ligand maintains a more conservative approach. Understanding these trends provides valuable insights into each company's operational focus and strategic priorities, offering a glimpse into their future trajectories in the biotech industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025